Please login to the form below

Not currently logged in
Email:
Password:

F2G appoints chief financial officer

Ralf Schmid brings experience from Nabriva Therapeutics

F2G Ralf SchmidManchester-based F2G Ltd has appointed Ralf Schmid as its new chief financial officer.

Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

He moves to F2G from Nabriva Therapeutics, where he had been a member of the management board since the Austrian biopharmaceutical company's inception in 2006.

Schmid first served as the firm's chief financial officer, before becoming chief executive officer, and most recently held the dual post of chief operating officer and chief financial officer.

 Ian Nicholson, chief executive of F2G, said: “Following our successful $60m financing, I am delighted to welcome Ralf to the F2G team.

“His strong track record in fundraising, M&A transactions and deal structuring will be invaluable as we continue to generate positive data from our clinical trials and position the company for success.”

14th July 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics